Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study.
Diabetes Res Clin Pract. 2019 Mar 04;:
Authors: Chen P, Xu X, Lin L, Yu Y, Chen S, Chen X, Shao Z
BACKGROUND: It has been reported that GLP-1 analogue can improve the skin lesions of psoriasis.However further research is needed to confirm that finding.
OBJECTIVE: The study can provide further data regarding the efficacy and safety of GLP-1 analogue liraglutide in the treatment of psoriasis patients with type 2 diabetes.
METHODS: We recruit 7 psoriasis patients with type 2 diabetes,and use hypodermic injection with liraglutide1.8 mg.In 12 weeks of treatment,we estimate the difference of before and after respectively,likeBMI,waist circumference,fasting blood glucose,fasting C-peptide,HbA1c,blood lipid levels,CRP,PASI,DLQI,skin tissue and pathological analysis of psoriasis.
RESULTS: After 12 weeks of treatment,the mean value of PASI decreased from 15.7±11.8 to 2.2±3.0 (P =0.03),while the DLQI decreased from 21.8±6 to 4.1±3.9 (P = 0.001).HbA1c was significantly improved after 12 weeks of treatment,decreased to 6.4±0.8% (P = 0.04),the BMI decreased to 21±3kg m-2 (P < 0.01),and the waist circumference was also significantly improved to 83±1cm (P < 0.05).And 12 weeks after , the fasting C-peptide levels increased to 1.9±0.5ng/ml (P = 0.006),HOMA - IR fell to 1.6 ±0.6 (P = 0.03).Histological analysis showed a reduction in epidermal thickness after treatment.The mean PASI decreased from 15.7 (1.5-31.3) to 2.0 (0.3-8.7) (P = 0.03),the DLQI decreased from 22 (8-27) to 4 (0-10) (P = 0.001). CONCLUSION: GLP-1 analogueliraglutide can improve the skin lesions of psoriasis patients with type 2 diabetes effectively,especially for extremely severe psoriasis patients.Its therapeutic effect may be related to anti-inflammatory,hypoglycemic and reducing weight. PMID: 30844468 [PubMed - as supplied by publisher] Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study. PubMed:30844468 Last Update Posted: 03/08/19 06:03AM